Sanofi Avoids Patent Cliff For Now, Returns to Growing Sales And Profits In Third Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi's Q3 sales grow by 10% and net income by 4.1% as Genzyme acquisition compensates for increasing generic competition to leading products.